GE
EGRX

General Electric’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

General Electric’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-336,992
Closed -$13.1M – 184
2016
Q2 		$13.1M Hold
336,992
– – 0.07% 128
2016
Q1 		$13.6M Hold
336,992
– – 0.07% 123
2015
Q4 		$29.9M Hold
336,992
– – 0.14% 95
2015
Q3 		$24.9M Hold
336,992
– – 0.06% 100
2015
Q2 		$27.2M Sell
336,992
-386,506
-53% -$25.2M 0.06% 100
2015
Q1 		$30.3M Sell
723,498
-213,494
-23% -$6.06M 0.07% 100
2014
Q4 		$14.5M Buy
+936,992
New +$12M 0.03% 118

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

General Electric's EGRX Position: Q3 2016 in Review

General Electric sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2016, closing a stake of 336,992 shares — an estimated $13.1M sold.

General Electric first reported a position in EGRX in Q4 2014 and held it in 7 quarters. The position peaked at $30.3M in Q1 2015. 137 funds tracked by Wall St. Rank hold EGRX as of Q3 2016.

  • General Electric reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • General Electric sold 336,992 Eagle Pharmaceuticals, Inc. shares in Q3 2016, an estimated $13.1M.
  • General Electric first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2014 and held it in 7 quarters.
  • General Electric's Eagle Pharmaceuticals, Inc. position peaked at $30.3M in Q1 2015.
  • 137 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2016.

Based on General Electric's 13F filing for Q3 2016, filed 10 Nov 2016.